Patient characteristics at baseline, stratified for anticoagulation class
| Variable (at study index) . | Anticoagulation class at index . | |
|---|---|---|
| DOAC* . | LMWH† . | |
| All patients, n | 41 | 55 |
| Age, median (IQR), y | 66 (58-74) | 64 (57-71) |
| Sex | ||
| Male | 27 (65.9) | 28 (50.9) |
| Female | 14 (34.1) | 27 (49.1) |
| Primary cancer type | ||
| Lung | 23 (56.1) | 31 (56.4) |
| Renal cell | 3 (7.3) | 2 (3.6) |
| Breast | 1 (2.4) | 8 (14.6) |
| Esophageal | 7 (17.1) | 4 (7.3) |
| Other‡ | 7 (17.1) | 10 (18.2) |
| Cancer status | ||
| Newly diagnosed | 2 (4.9) | 6 (10.9) |
| Relapsed/refractory | 39 (95.1) | 49 (89.1) |
| Medical anticancer treatment (yes) | 23 (56.1) | 44 (80) |
| Radiotherapy | ||
| Stereotactic radiosurgery | 20 (48.8) | 23 (41.8) |
| Whole brain radiotherapy | 6 (14.6) | 13 (23.6) |
| None | 14 (34.2) | 17 (30.9) |
| Missing | 1 (2.4) | 2 (3.6) |
| Prior neurosurgery (yes) | 4 (9.8) | 5 (9.1) |
| Anticoagulation dose | ||
| Full | 37 (90.2) | 48 (87.3) |
| Intermediate | 0 | 7 (12.7) |
| Secondary prophylaxis | 4 (9.8) | 0 |
| Indication for anticoagulation | ||
| VTE | 22 (53.7) | 49 (89.1) |
| Atrial fibrillation | 19 (46.3) | 6 (10.9) |
| Comorbidities | ||
| Hypertension | 20 (48.8) | 15 (27.3) |
| Chronic kidney disease | 8 (19.5) | 4 (7.3) |
| Prior ischemic stroke§ | 4 (9.8) | 5 (9.1) |
| Aspirin therapy (yes) | 2 (4.9) | 2 (3.6) |
| PANWARDS score|| | ||
| High ICH risk (≥25) | 26 (63.4) | 25 (45.5) |
| Low ICH risk (<25) | 14 (34.2) | 28 (50.9) |
| Missing | 1 (2.4) | 2 (3.6) |
| Study center | ||
| Amsterdam | 24 (58.5) | 21 (38.2) |
| Rabin | 17 (41.5) | 34 (61.8) |
| Variable (at study index) . | Anticoagulation class at index . | |
|---|---|---|
| DOAC* . | LMWH† . | |
| All patients, n | 41 | 55 |
| Age, median (IQR), y | 66 (58-74) | 64 (57-71) |
| Sex | ||
| Male | 27 (65.9) | 28 (50.9) |
| Female | 14 (34.1) | 27 (49.1) |
| Primary cancer type | ||
| Lung | 23 (56.1) | 31 (56.4) |
| Renal cell | 3 (7.3) | 2 (3.6) |
| Breast | 1 (2.4) | 8 (14.6) |
| Esophageal | 7 (17.1) | 4 (7.3) |
| Other‡ | 7 (17.1) | 10 (18.2) |
| Cancer status | ||
| Newly diagnosed | 2 (4.9) | 6 (10.9) |
| Relapsed/refractory | 39 (95.1) | 49 (89.1) |
| Medical anticancer treatment (yes) | 23 (56.1) | 44 (80) |
| Radiotherapy | ||
| Stereotactic radiosurgery | 20 (48.8) | 23 (41.8) |
| Whole brain radiotherapy | 6 (14.6) | 13 (23.6) |
| None | 14 (34.2) | 17 (30.9) |
| Missing | 1 (2.4) | 2 (3.6) |
| Prior neurosurgery (yes) | 4 (9.8) | 5 (9.1) |
| Anticoagulation dose | ||
| Full | 37 (90.2) | 48 (87.3) |
| Intermediate | 0 | 7 (12.7) |
| Secondary prophylaxis | 4 (9.8) | 0 |
| Indication for anticoagulation | ||
| VTE | 22 (53.7) | 49 (89.1) |
| Atrial fibrillation | 19 (46.3) | 6 (10.9) |
| Comorbidities | ||
| Hypertension | 20 (48.8) | 15 (27.3) |
| Chronic kidney disease | 8 (19.5) | 4 (7.3) |
| Prior ischemic stroke§ | 4 (9.8) | 5 (9.1) |
| Aspirin therapy (yes) | 2 (4.9) | 2 (3.6) |
| PANWARDS score|| | ||
| High ICH risk (≥25) | 26 (63.4) | 25 (45.5) |
| Low ICH risk (<25) | 14 (34.2) | 28 (50.9) |
| Missing | 1 (2.4) | 2 (3.6) |
| Study center | ||
| Amsterdam | 24 (58.5) | 21 (38.2) |
| Rabin | 17 (41.5) | 34 (61.8) |
Values represent n (%) of patients unless otherwise indicated.
NSAID, nonsteroidal anti-inflammatory drug.
Specific DOAC types included apixaban (n = 11), dabigatran (n = 5), edoxaban (n = 8), and rivaroxaban (n = 17).
Specific LMWH types included enoxaparin (n = 34), nadroparin (n = 15), and tinzaparin (n = 6).
Other cancer types (n ≤ 2) include cervical, colon, diffuse large B-cell lymphoma, germ-cell tumor, ovarian, sarcoma, sarcomatoid carcinoma, squamous cell carcinoma of parotid, urothelial carcinoma, thymic neuroendocrine, or unknown origin.
Evidence of prior ischemic stroke on baseline neuroimaging studies.
PANWARDS risk score for predicting ICH on therapeutic anticoagulation15 classified as either high (score ≥25) or low (score <25) ICH risk.